

February 7, 2022

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--	---

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

This has reference to our intimation dated January 28, 2022.

The Board of Directors of the Company at its meeting held today i.e. February 7, 2022, inter alia, approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2021.

A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1.


The Board of Directors at its meeting held today also inter-alia recommended to the shareholders, by way of postal ballot, the appointment of Mr. Pradip Kanakia (DIN: 00770347) as the Independent Director of the Company w.e.f. October 18, 2021. The details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed herewith as Annexure 2.

The Board meeting commenced at 12:00 noon (IST) and concluded at 3:00 p.m. (IST).

This is for your information and record please.


Encl.: a/a


Thanking You,
For **Camlin Fine Sciences Limited**



Rahul Sawale
Company Secretary
& VP - Legal

 **Registered Office:**
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlinfo.com

 www.camlinfo.com

PART I	STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021											
	PARTICULARS	STANDALONE				CONSOLIDATED				YEAR ENDED 31.03.2021	YEAR ENDED 31.03.2021	
		QUARTER ENDED 30.09.2021	31.12.2020	31.12.2021	31.12.2020	QUARTER ENDED 30.09.2021	31.12.2020	31.12.2021	31.12.2020			NINE MONTHS ENDED 31.12.2021
1	Revenue from operations	20,022.37	13,816.59	48,411.81	43,158.91	60,004.83	31,121.94	29,792.48	102,286.41	86,047.90	118,710.31	498.42
2	Other income	724.81	100.90	1,114.60	373.16	546.83	61.98	114.29	1,171.62	289.12	498.42	
3	Total income	20,747.18	13,917.49	49,526.41	43,532.07	60,551.66	31,183.92	29,906.77	103,458.03	86,337.02	119,208.73	
4	Expenses	12,430.37	7,614.18	28,009.93	29,416.57	38,417.99	14,056.36	12,415.82	53,558.09	33,968.84	48,803.22	
	Cost of materials consumed	26.92	20.65	324.80	353.85	1,604.49	782.65	2,007.45	3,050.38	6,752.26	7,813.59	
	Purchase of stock in trade	(567.20)	978.28	(1,058.88)	657.11	(2,182.59)	2,252.33	(1,007.83)	(935.59)	1,032.34	1,732.00	
	Changes in inventories of finished goods/WIP/stock in trade	1,528.35	1,310.33	3,968.77	2,718.35	3,869.86	3,454.81	3,145.61	10,729.32	8,527.30	12,038.31	
	Employee benefits expense	644.88	748.58	809.87	2,354.10	3,253.65	681.92	675.07	2,600.90	2,542.97	3,752.77	
	Finance costs	672.21	662.16	1,978.46	1,272.01	1,928.30	1,324.48	1,335.55	4,002.37	3,246.81	4,429.42	
	Depreciation and amortisation expense	4,291.07	3,598.24	10,831.04	9,021.52	12,107.82	8,304.53	8,554.01	23,036.09	22,617.35	30,129.85	
	Other expenses	19,026.60	14,932.42	48,124.21	42,569.76	58,999.52	31,093.17	27,125.68	96,041.56	78,687.87	108,699.16	
5	Total Expenses	1,720.58	(1,014.93)	489.56	962.31	1,552.14	90.75	2,781.09	7,416.47	7,649.15	10,509.57	
6	Profit / (loss) before exceptional items and share of profit / (loss) of associate (3-4)	1,720.58	(1,014.93)	489.56	962.31	1,552.14	90.75	2,781.09	7,416.47	7,649.15	10,509.57	
7	Exceptional items	-	-	-	50.32	50.32	-	-	-	-	-	
8	Profit / (loss) before share of profit / (loss) of associate (5-6)	1,720.58	(1,014.93)	489.56	1,012.63	1,602.46	90.75	2,781.09	7,416.47	7,649.15	10,509.57	
9	Share of profit / (loss) of associate	-	-	-	-	-	(14.57)	-	(16.97)	-	0.06	
10	Profit / (loss) before tax (7-8)	1,720.58	(1,014.93)	489.56	1,012.63	1,602.46	76.18	2,781.09	7,399.50	7,649.15	10,509.63	
11	Tax Expenses	314.15	(183.48)	91.58	168.03	277.92	677.95	588.84	2,391.08	1,853.39	2,735.69	
12	- Current tax	168.33	(132.34)	62.47	133.97	395.78	470.64	250.38	303.92	831.69	1,238.14	
12	- Deferred tax	482.48	(315.82)	154.05	389.99	297.40	673.70	839.22	2,695.00	2,685.08	3,973.83	
13	Profit / (loss) for the period (9-10)	1,238.10	(699.11)	335.51	614.59	828.12	(388.41)	1,941.87	4,704.50	4,964.07	6,535.80	
14	Other comprehensive income	(84.14)	(24.66)	(99.77)	(16.58)	(49.46)	(24.66)	(7.71)	(99.77)	(16.58)	(55.36)	
15	Items that will not be reclassified to profit or loss	29.41	5.46	31.71	5.79	11.49	29.41	2.69	31.71	5.79	13.50	
16	Remeasurements of defined benefit plans	-	-	-	-	-	-	-	-	-	-	
17	Changes in revaluation surplus	-	-	-	-	-	-	-	-	-	-	
18	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	
19	Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	
20	Exchange differences on translating the financial statements of foreign operations	-	-	-	-	-	-	-	-	-	-	
21	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	
22	Other comprehensive income	(54.73)	(19.20)	(68.06)	(10.79)	(37.97)	(178.40)	1,158.99	(458.63)	2,047.60	11,350.04	
23	Total comprehensive income for the period (11+12)	1,183.37	(718.31)	330.49	944.15	603.80	2,536.85	3,100.86	4,245.87	7,011.67	17,885.84	
24	Profit / (loss) attributable to:											
25	(i) Owners of the Company						2,872.47	1,541.94	4,554.76	3,669.81	5,096.34	
26	(ii) Non-controlling interests						(157.22)	399.93	149.74	1,294.26	1,439.46	
27	Other comprehensive income attributable to:											
28	(i) Owners of the Company						(402.66)	743.29	(711.95)	1,482.57	10,936.97	
29	(ii) Non-controlling interests						224.26	415.70	253.32	565.03	413.07	
30	Total comprehensive income attributable to:											
31	(i) Owners of the Company						2,469.81	2,285.23	3,842.81	5,152.38	16,033.31	
32	(ii) Non-controlling interests						67.04	815.63	403.06	1,859.29	1,852.53	
33	Paid-up Equity Share Capital (Face Value Re.1/- per share)						1,276.28	1,274.72	1,276.02	1,274.72	1,274.98	
34	Other Equity						45,188.57				63,065.10	
35	Earnings per Share (EPS) (of Re.1/- each) (not annualised)						2.25	(0.43)	3.57	3.00	4.13	
36	Basic (Rs.)						0.67	(0.37)	3.01	2.73	3.68	
37	Diluted (Rs.)						0.60	(0.37)	3.01	2.73	3.68	

Registered Office:

Camlin Fine Sciences Ltd, F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
 CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

+91 22 6700 1000

+91 22 2832 4404

corporate@camlins.com

www.camlins.com



Notes to financial results:
 1 The above results which are published in accordance with Regulation 35 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 7, 2022. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time.
 2 Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED				
	QUARTER ENDED		NINE MONTHS ENDED		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
	31.12.2021 (Unaudited)	30.09.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)	31.12.2020 (Unaudited)	30.09.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)
Other Income	217.70	-	-	391.76	-	-	-	490.76	-
Other Expense	-	94.31	245.75	-	977.25	503.37	192.87	-	1,399.89
Total Exchange gain / (loss)	217.70	(94.31)	(245.75)	391.76	(977.25)	(503.37)	(192.87)	490.76	(1,488.52)

3 Finance costs include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED				
	QUARTER ENDED		NINE MONTHS ENDED		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED
	31.12.2021 (Unaudited)	30.09.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)	31.12.2020 (Unaudited)	30.09.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)
Exchange gain	46.34	-	71.58	-	249.99	224.79	327.20	-	588.66
Exchange loss	-	97.84	-	149.80	-	-	-	22.45	-
Total Exchange gain / (loss)	46.34	(97.84)	71.58	(149.80)	249.99	224.79	327.20	(22.45)	588.66

4 During the nine months ended December 31, 2021, the Company has issued and allotted 129,900 equity shares of Re.1 each at a premium of Rs. 49 per equity share aggregating to INR 64.95 lakh under Employees Stock Option Scheme, 2018 (ESOP-2018). 6,000 employee stock options have lapsed under ESOP-2018 during nine months ended December 31, 2021 and have formed part of the Scheme. No employee stock options under ESOP-2020 have lapsed during nine months ended December 31, 2021.

5 Supreme People's Court of China vide its judgement dated February 19, 2021 had imposed a penalty of RMB 159.32 million (about USD 25 million / INR 18,000 lakh) including right protection cost of RMB 3.49 million (about USD 0.55 million / INR 380 lakh) on our JV partner Wanglong Technology (being 49% stake holder in Company's subsidiary CFS Wanglong Flavors (Ningbo) Co., Ltd. (CFSWL) & others for alleged infringement of intellectual property used in the process for manufacturing Vanillin. Further, 7% of the aforesaid penalty amounting to RMB 11.15 million (about USD 1.70 million / INR 1,265 lakh) had also been levied to the subsidiary Company. Consequent to the Order, as an abundant legal caution, the production of Vanillin at the subsidiary's manufacturing facility in China has been stopped till further directions of the Court.

In the opinion of the management, based on the discussions with the JV Partner, the findings and allegations of the Honourable Court are not based on the facts and that the order passed by the Court is arbitrary. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Supreme People's Court of China which was heard in the month of October 2021, the decision thereof is awaited. The management is confident of a favourable decision in the retrial proceedings and that no penalty will be sustained and that consequently the production is expected to restart in a very near future.

Further in terms of the shareholders' agreement dated April 28, 2017 and its subsequent amendments, Company and its subsidiary, CFSWL, are indemnified against penalty and or legal consequences emanating from the violation of IP rights. Under these circumstances, no impairment of the investment value of CFSWL and or other receivables is envisaged at this juncture in standalone financial results. Similarly, no impairment of goodwill and /or property, plant and equipment is envisaged in the consolidated financial results.

6 On November 17, 2021, the Company has acquired additional 33.5% stake in its subsidiary in Mexico viz, Dresen Quimica for a total consideration of USD 8.5 million equivalent to INR 6,290 lakh. Pursuant to the above, the Company directly as well as through its wholly owned subsidiary, CFS Blends, which was incorporated on September 24, 2021, hold a stake of 98.5% in Dresen Quimica.

7 During the quarter, the Company has acquired equity stake and also invested in AlgalR Nutrapharma Private Limited (AlgalR) for a total investment amounting to INR 644 lakh. Pursuant to the above, the Company holds 80% stake in the equity share capital of AlgalR with effect from November 11, 2021.

8 Pursuant to the directions of the Honourable Supreme Court dated December 14, 2020, National Green Tribunal has reheard the matter regarding the compensation for alleged violations of environmental norms by manufacturers at Tarapur MIDC and vide its direction dated January 24, 2022 has enhanced the portion of compensation attributable to the Company from INR 515.56 lakh to an amount of INR 1,712.28 lakh. Company is in process of pursuing further legal action against the said directions. Based on management assessment, the Company believes that it has strong grounds to defend its position against the National Green Tribunal's direction and hence no provision is considered necessary in these financial results in respect of the penalty levied on the Company.

9 The Company's operations constitute a single business segment in Fine Chemicals.

10 Figures for previous periods have been regrouped/rearranged wherever necessary.

FOR CAMLIN FINE SCIENCES LIMITED


 Ashish S. Dandekar
 Chairman & Managing Director



Place: Mumbai
 Date: February 7, 2022



Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.

CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors
Camlin Fine Sciences Limited,
WICEL, F-11/12, Opp. SEEPZ Main Gate,
Central Road, SEEPZ,
Andheri- (East).

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Camlin Fine Sciences Limited (“the Company”), for the quarter ended December 31, 2021 and for the period from April 1, 2021 to December 31, 2021 (“the Statement”). This Statement which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We draw attention to Note 5 to the Financial Results relating to the decision of the Supreme People’s Court of China (“Honorable Court”) which has imposed penalty amounting to RMB 159.32 million on the JV partner of the subsidiary company and others for alleged infringement of intellectual property used in the manufacturing process. An amount of RMB 11.15 million i.e. INR 1265 lakh which is 7% of the total penalty imposed is attributed to the subsidiary i.e. CFS Wanglong Flavours (Ningbo) Co. Ltd. As an abundant legal caution, the Company has stopped the production facility till further directions of the Honorable Court. As per the terms of the shareholders’ agreement dated April 28, 2017 and amendments made thereafter, the company and its




LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

subsidiary company are indemnified against penalty and or legal consequences emanating from the violation of the IP rights. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Honorable Court which was heard in the month October 2021, the decision thereof is awaited. In the opinion of the Management, based on the above and for reasons as more fully discussed in the aforesaid note, no impairment of the investment value or in respect of other receivables from the subsidiary company is required.

Our opinion is not modified in respect of these matters.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA
PARTNER
Membership Number 127355
UDIN: 22127355AAQYMV7335**

Place: Mumbai
Date: February 7, 2022

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors
Camlin Fine Sciences Limited
WICEL, F-11/12, Opp. SEEPZ Main Gate,
Central Road, SEEPZ,
Andheri- (East), Mumbai-400096

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Camlin Fine Sciences Limited (the "Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and two associates for the quarter ended December 31, 2021 and for the period from April 01, 2021 to December 31, 2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. We draw attention to Note 5 to the Financial Results relating to the decision of the Supreme People's Court of China ("Honorable Court") which has imposed penalty amounting to RMB 159.32 million on the JV partner of the subsidiary company and others for alleged infringement of intellectual property used in the manufacturing process. An amount of RMB 11.15 million i.e. INR 1,265.00 lakhs which is 7% of the total penalty imposed is attributed to the subsidiary i.e. CFS Wanglong Flavours (Ningbo) Co. Ltd. As an abundant legal caution, the Company has stopped the production facility till further directions of the Honorable Court. As per the terms of the shareholders' agreement dated April 28, 2017 and amendments made thereafter, the company and its subsidiary company are indemnified against penalty and or legal consequences emanating from the violation of the IP rights. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Honorable Court which was heard in the month October 2021, the decision thereof is awaited. In the opinion of the Company's Management, based on the above and for reasons as more fully discussed in the aforesaid note, no impairment of cash generating unit consisting of property, plant and equipment



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

of the said subsidiary or on goodwill on consolidation in respect of the said subsidiary company is required.

Our opinion is not modified in respect of this matter.

5. The Statement includes the results of the following entities:
- i. CFS Europe S.p.A.
 - ii. CFS Do Brasil Importacao E Exportacao De Aditivos Alimenticios LTDA
 - iii. Solentus North America Inc
 - iv. CFS North America LLC
 - v. Dresen Quimica, S.A.P.I. de C.V.
 - vi. Inovel, S.A.S.
 - vii. Industrias Petrotec De Mexico S.A De C.V.
 - viii. Nuvel, S.A.C.
 - ix. Britec, S.A.
 - x. Grinel, S.R.L.
 - xi. Chemolutions Chemicals Ltd.
 - xii. CFS Wanglong Flavours (Ningbo) Co. Ltd.
 - xiii. CFS Argentina S.A.
 - xiv. CFS Chile S.p.A
 - xv. CFS Pahang Asia Pte Ltd.
 - xvi. CFS De Mexico Blends S.A.P.I De C.V
 - xvii. Fine Lifestyle Brands Ltd.
 - xviii. AlgalR Nutra Pharms Private Limited (Associate upto November 11, 2021 and thereafter subsidiary)
6. Based on our review and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial results of twelve subsidiaries incorporated outside India and a subsidiary in India included in the Statement, whose interim financial results reflect total revenues of Rs. 21,463.06 lakhs and Rs. 65,362.66 lakhs, total net profit after tax of Rs. 867.31 lakhs and Rs. 3,190.68 lakhs and total comprehensive income of Rs. 760.42 lakhs and Rs. 2,939.21 lakhs for the quarter and for the period from April 01, 2021 to December 31, 2021 respectively. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

In respect of ten subsidiaries located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which has been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the interim financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the




Company's management. Our conclusion in so far as it relates to amounts and disclosures included in respect of such subsidiaries located outside India is based on the reports of the other auditors and the conversion adjustments made by the management of the Company and reviewed by us.

Our conclusion on the statement is not modified in respect of the above matter.

8. The Statement includes interim financial results of four subsidiaries incorporated outside India included in the Statement, whose interim financial results reflect total revenues of Rs. 732.70 lakhs and Rs. 1,511.54 lakhs, total net profit after tax of Rs. (21.00) lakhs and Rs. (41.57) lakhs and total comprehensive income of Rs. (26.70) lakhs and Rs. (70.91) lakhs for the quarter and for the period from April 01, 2021 to December 31, 2021 respectively. The Statement also includes group's share of net profit of Rs. Nil and Rs.(16.97) lakhs for the quarter and for the period from April 01, 2021 to December 31, 2021 in respect of an associate companies. These interim financial results of five subsidiaries are not reviewed as of the date of this report and have been included in the interim financial results on the basis of the Unaudited Management Accounts. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA
PARTNER
Membership Number 127355**

UDIN: 22127355AAQYZE9230

Place: Mumbai

Dated: February 7, 2022

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021													
No.	PARTICULARS	STANDALONE						CONSOLIDATED					
		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED		
		31.12.2021 (Unaudited)	30.09.2021 (Unaudited)	31.12.2021 (Unaudited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	31.12.2021 (Unaudited)	30.09.2021 (Unaudited)	31.12.2021 (Unaudited)	31.12.2021 (Unaudited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	
1	Total Income from Operations	20,022.37	13,816.59	48,411.81	38,081.83	60,004.83	31,121.94	102,286.41	29,792.48	86,047.90	118,710.31		
2	Net Profit / (Loss) from ordinary activities after tax	1,238.10	(699.11)	1,012.21	2,715.25	828.12	(388.41)	4,704.50	1,941.87	4,964.07	6,535.80		
3	Net Profit / (Loss) from the period after tax and non-controlling interests (after extraordinary items)				2,872.47		(553.41)	4,554.76	1,541.94	3,669.81	5,096.34		
4	Total Comprehensive Income for the period	1,183.37	(718.31)	944.15	2,536.85	790.15	(1,009.16)	4,245.87	3,100.86	7,011.67	17,885.84		
5	Equity Share Capital	1,276.28	1,276.02	1,276.28	1,276.28	1,274.98	1,276.02	1,276.28	1,274.72	1,274.98	1,274.98		
6	Other Equity					45,188.57							
7	Earnings per share (before and after extraordinary items) (of Re 1/-each)	0.97	(0.55)	0.79	2.25	0.67	(0.43)	3.57	1.26	3.00	4.13		
	-Basic Rs.	0.82	(0.46)	0.67	1.90	0.60	(0.37)	3.01	1.15	2.73	3.68		
	-Diluted Rs.												

The above information is an extract of the detailed format of unaudited results for the quarter and nine months ended December 31, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter and nine months ended December 31, 2021 are available on the Company's website, www.camlinfs.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.



FOR CAMLIN FINE SCIENCES LIMITED



Ashish S. Dandekar
Chairman & Managing Director

Place: Mumbai
Date: February 7, 2022

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

Appointment of Mr. Pradip Kanakia as Independent Director

Sr. No.	Particulars	Details
1	Reason	Recommended to the shareholders, by way of postal ballot, the appointment of Mr. Pradip Kanakia (DIN: 00770347) as the Independent Director of the Company.
2	Date of appointment & term of appointment	w.e.f. October 18, 2021 upto October 17, 2026
3	Brief profile	<p>Mr. Pradip M. Kanakia, a qualified Chartered Accountant (from The Institute of Chartered Accountants of India and in England and Wales), is a strong leader and governance oriented professional with expertise in strategy, transformation, performance management, accounting, auditing, reporting, controls, compliance and governance.</p> <p>He has held leadership positions with Price Waterhouse and KPMG during a career spanning 35 years. As a lead audit partner, he has led and signed audits of several prestigious Indian and multinational companies, across various industry sectors for over 22 years. Several of these companies have won prestigious awards for the Best Presented Annual Reports. As a leader in both Price Waterhouse and KPMG, he played a major role in transforming the businesses of both the firms leading to accelerated growth and profitability by demonstrating the ability to ‘turn around’ underperforming business units with strong strategic and execution skills. He has led several thousand people in both the firms and cultivated a culture of high performance, collaboration and teamwork. Mr. Pradip ran a flagship Independent Directors’ programme in Price Waterhouse that covered most relevant and topical areas around governance. Through this program, Mr. Pradip has cultivated strong relationships with leading Directors, CFOs, CEOs and other C suite professionals of leading companies across the country.</p>
4	Disclosure of relationship between directors	Not related to any other Director / Key Managerial Personnel